Antiulcer activity of 2-phenyl-9-diethylaminoethylimidazo[1,2-a]benzimidazole dinitrate in ethanol-prednisolone damage to gastric mucosa


Cite item

Full Text

Abstract

Nowadays, the search for new effective and safe medicines for the treatment of acid-dependent gastrointestinal diseases remains an urgent problem of modern pharmacology.The aim of this study was an experimentally study of the anti-ulcer activity of 2-phenyl-9-diethylaminoethylimidazo[1,2-a]benzimidazole dinitrate on the model of damage to the gastric mucosa caused by the administration of 80% ethanol and prednisolone combination (20 mg/kg).Materials and methods. To simulate the damage to the gastric mucosa, the experimental animals (white male Wistar rats) were administrated with prednisone at the rate of 20 mg/kg and 80% ethyl alcohol at the dose of 0.6 ml/100 g of the animal body weight. Prednisolone was dissolved in 80% alcohol. Antisecretory antiulcer agents actively used in clinical practice, were selected as reference drugs: ranitidine (30 mg/kg, 10 mg/kg and 3 mg/kg) and omeprazole (3 mg/kg, 1 mg/kg and 0.3 mg/kg). The studied compound was used at the doses of 30 mg/kg, 10 mg/kg and 3 mg/kg. All the substances under study were administered intragastrically with the use of an atraumatic probe. Results. It has been established that the benzimidazole derivative in the studied doses contributes to a dose-dependent reliable reduction in the area and depth of ulcerative lesions of the gastric mucosae relative to the control and reference drugs (ranitidine and omeprazole). In addition, in the maximum studied dose (30 mg/kg), the proportion of the animals with ulcerative lesions significantly decreases by more than 2 times. The calculated ED50 values for the benzimidazole derivative and ranitidine were 5.09 mg/kg and 38.23 mg/kg, respectively.Conclusion. The obtained experimental data indicate that the benzimidazole derivative has a pronounced dose-dependent antiulcer effect on the model of ethanol-prednisolone erosive-ulcerous defects of the rats’ gastric mucosae, which is superior to the effects of the reference preparations. It makes its further study promising.

About the authors

M. V. Chernikov

Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical University

Email: pharmax@list.ru

M. A. Oganova

Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical University

Email: marina-oganova81@mail.ru

S. A. Kalashnikova

Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical University

Email: kalashnikova-sa@yandex.ru

L. V. Polyakova

Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical University

Email: lypolyakova7@gmail.ru

N. A. Khromova

Pyatigorsk Medical and Pharmaceutical Institute - branch of Volgograd State Medical University

Email: khromovanatasha1994@gmail.com

References

  1. Фундаментальные основы кислотопродукции в желудке / И.В. Маев, Д,Н. Андреев, А.В. Заборовский // Медицинский совет. - 2018. - № 3. - с. 7-14. Doi: https://doi.org/10.21518/2079701X-2018-3-7-14.
  2. Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr. Opin. Gastroenterol. - 2017. - V. 33, №6. P. 430-438. doi: 10.1097/MOG.0000000000000392.
  3. Salahuddin A. Benzimidazoles: A biologically active compounds / A. Salahuddin, M. Shaharyar, A. Mazumder // Arabian J. Chem. - 2017. - № 10. - P. 157-173.
  4. Пат. Antiulcer benzimidazole derivatives/ Hockley M.H., Titman R.B. / US 4767769 A; № US 07/065,363; заявл. 23.06.1987; опубл. 30.08.1988. - Режим доступа: https://patents.google.com/patent/US4767769A/en
  5. Спасов А.А., Петров В.И., Анисимова В.А., Минкин В.И., Черников М.В. Лекарственная субстанция для подавления геликобактероподобных эрозивно-язвенных повреждений слизистой оболочки желудка. Патент RU 2395282 С2. Бюл. №21, 2010.
  6. Черников М.В., Оганова М.А., Герасименко А.С., Артемьев Е.А. Противоязвенная активность динитрата 2-фенил-9-диэтиламиноэтилбензимидазола при геликобактероподобном повреждении слизистой оболочки желудка / Фармация и фармакология. 2018. Т. 6. №4. С. 367-380. Doi: https://doi.org/10.19163/2307-9266-2018-6-4-367-379.
  7. Черников М.В., Оганова М.А., Герасименко А.С., Артемьев Е.А. Изучение антисекреторной активности динитрата 2-фенил-9-диэтиламиноэтилимидазобензимидазола методом непрерывной перфузии желудка крыс / Фармация и фармакология. 2019. Т. 7. №4. С. 231-240. Doi: https://doi.org/10.19163/2307-9266-2019-7-4-231-240.
  8. Caplan A., Fett N., Rosenbach M., Werth V.P., Micheletti R.G. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects / J. Am. Acad. Dermatol. - 2017. - V. 76, №1. P. 11-16.
  9. Подвигина Т.Т., Филаретова Л.П. Двойственные эффекты глюкокортикоидных гормонов на слизистую оболочку желудка / Успехи физиологических наук. - 2014. - Т. 45. - №4. - С. 19-33.
  10. Багинская А.И., Ферубко Е.В., Курманова Е.Н. и др. Экспериментальное моделирование в гастроэнтерологии. Практические рекомендации. Часть II. Экспериментальные модели «острых» язв желудка / Вопросы биологической, медицинской и фармацевтической химии, 2016. - №3. - С. 32-40.
  11. Simoes S., Lopes R., Campos M.C.D., Marruz M.J., da Cruz M.E.M., Corvo L. Animal models of acute gastric mucosal injury: Macroscopic and microscopic evaluation / Animal Model Exp. Med. - 2019. - №2. P. 121-126.
  12. Руководство по проведению доклинических исследований лекарственных средств. Часть первая / под ред. А.Н. Миронов, Н.Д. Бунатян, А.Н. Васильев и др. // М.: Гриф и К, 2012. - 944 с.
  13. ГОСТ Р 33044-2014. Принципы надлежащей лабораторной практики. (OECD Guide 1:1998, IDT). - М.: Стандартинформ, 2015. - 11 с.
  14. Приказ Министерства здравоохранения РФ от 1 апреля 2016 г. № 199н «Об утверждении Правил надлежащей лабораторной практики» (Зарегистрировано в Минюсте РФ 15 августа 2016 г. № 43232) // Бюллетень нормативных актов федеральных органов исполнительной власти, № 37, 2016.
  15. Adinortey M.B. In vivo models used for evaluation of potential antigastroduodenal ulcer / M.B. Adinortey, C. Ansah, I.Galyuon, A. Nyarko // Ulcers. - 2013. - Vol. 2013. - P. 1-12.. - Режим доступа: http://dx.doi.org/10.1155/2013/796405.
  16. Viswanatha Swamy A.H.M., Sajjan M., Thippeswamy A.H.M., Koti B.C., Sadiq A.J. Influence of Proton Pump Inhibitors on Dexamethasone-Induced Gastric Mucosal Damage in Rats / Indian J. Pharm. Sci., 2011. -V. 73, №2. P. 193-198. doi: 10.4103/0250474x.91582
  17. Luo J.C., Shin V.Y., Liu E.S. et al. Dexamethasone delays ulcer healing by inhibition of angiogenesis in rat stomachs // Eur. J. Pharmacol., 2004. - V. 485. - P. 275-281. Doi: 10.1016/j. ejphar.2003.11.038
  18. Luo J.C., Chi C.W., Lin H.Y. et al. Dexamethasone inhibits epidermal growth factor-stimulated gastric epithelial cell proliferation // J. Pharmacol. Exp. Ther., 2007. - V. 320. - P. 687-694. DOI: 10.1124/ jpet.106.113035.
  19. Zhou B., Li B., Yi W. et al. Synthesis, antioxidant, and antimicrobial evaluation of some 2-arylbenzimidazole derivatives // Bioorg. Med. Chem. Lett. - 2013. - V. 23, №13. - P. 3759-3763. doi: 10.1016/j.bmcl.2013.05.004. doi: 10.1016/j.bmcl.2013.05.004
  20. Ates-Alagoz Z. Antioxidant activities of retinoidal benzimidazole or indole derivatives in In vitro model systems / Current Med. Chem. - 2013. - Vol. 20, №36. - P. 4633-4639.
  21. Gaba M., Singh S., Mohan C. et al. Design, Synthesis and Pharmacological Evaluation of Gastro-protective Antiinflammatory Analgesic Agents based on Dual Oxidative Stress / Cyclooxygenase Inhibition /Antiinflamm. Antiallergy Agents Med. Chem. - 2019. doi: 10.2174/1871523018666190325155244.

Copyright (c) 2019 Chernikov M.V., Oganova M.A., Kalashnikova S.A., Polyakova L.V., Khromova N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies